Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study

Archives of Medical Research

Volumn 46, Issue 4, 2015, Pages 280-285

  Samsami kor, Maryam ^a   Daryani, Naser Ebrahimi ^b   Asl, Parisa Rezanejad ^c   Hekmatdoost, Azita ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti oxidant; Inflammation; Resveratrol; Ulcerative colitis

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; AZATHIOPRINE; CAROTENOID; CORTICOSTEROID; FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; PLACEBO; RESVERATROL; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; SELENIUM; TUMOR NECROSIS FACTOR ALPHA; ZINC; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; STILBENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; FEMALE; FOLLOW UP; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; THERAPY; ULCERATIVE COLITIS; ADULT; BLOOD; COLITIS, ULCERATIVE; MIDDLE AGED; QUESTIONNAIRE; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; STILBENES; YOUNG ADULT;

EID: 84936945451     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.05.005     Document Type: Article

References (22)

1. Danese S., Fiocchi C. Ulcerative colitis. N Engl J Med 2011, 365:1713-1725.
2. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002, 17:S176-S185.
3. Yao J., Wang J.Y., Liu L., et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 2010, 41:288-294.
4. Martín A.R., Villegas I., Sánchez-Hidalgo M., et al. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006, 147:873-885.
5. Cui X., Jin Y., Hofseth A.B., et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) 2010, 3:549-559.
6. Abdallah D.M., Ismael N.R. Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats. Can J Physiol Pharmacol 2011, 89:811-818.
7. Sanchez-Fidalgo S., Cardeno A., Villegas I., et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 2010, 633:78-84.
8. Singh U.P., Singh N.P., Busbee B., et al. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol 2012, 31:66-84.
9. Singh U.P., Singh N.P., Singh B., et al. Role of resveratrol-induced CD11b+ Gr-1+ myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3+ T cells and amelioration of chronic colitis in IL-10-/- mice. Brain Behav Immun 2012, 26:72.
10. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
11. Verissimo R. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J Gastrointestin Liver Dis 2008, 17:439-444.
12. Casellas F., Alcalá M.J., Prieto L., et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004, 99:457-461.
13. Gholamrezaei A., Haghdani S., Shemshaki H., et al. Linguistic Validation of the Inflammatory Bowel Disease Questionnaire-Short Form (IBDQ-9) in Iranian Population. J Isfahan Med School 2011, 28:1850-1859.
14. Malekyian E.F., Shavandi N., Saremi A. The effect of one session Resvin (resveratrol) supplementation on total antioxidant capacity' superoxide dismutase and creatine kinase in elite women volleyball players. ZUMS J 2013, 21:64-75.
15. Singh U.P., Singh N.P., Singh B., et al. Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 2010, 332:829-839.
16. Faghihzadeh F., Adibi P., Rafiei R., et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014, 34:837-843.
17. Udenigwe C.C., Ramprasath V.R., Aluko R.E., et al. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 2008, 66:445-554.
18. Bo S., Ciccone G., Castiglione A., et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 2013, 20:1323-1331.
19. Timmers S., Konings E., Bilet L., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
20. Ren Z., Wang L., Cui J., et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie 2013, 68:689-694.
21. Busch F., Mobasheri A., Shayan P., et al. Resveratrol modulates interleukin-1beta-induced phosphatidylinositol 3-kinase and nuclear factor kappaB signaling pathways in human tenocytes. J Biol Chem 2012, 287:38050-38063.
22. Tibble J., Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001, 7:460-465.